Background: Current evidence suggests that blood eosinophil levels (Eos) are associated with chronic obstructive pulmonary disease (COPD) treatment response and natural history. This analysis investigated the relationship between Eos levels and clinical characteristics in a representative cohort of US subjects with spirometry-defined COPD. Methods: Cross-sectional data from the National Health And Nutrition Examination Survey (NHANES 2007e2010) of subjects 40 years with spirometry-defined COPD and Eos data (n ¼ 948) were analyzed. Differences in clinical characteristics by Eos level (2%, >2%) were compared using chi-square tests. Characteristics associated with Eos >2% were identified using multivariate logistic regression modeling. Characteristics associated with Eos >2% among subjects with normal lung function, plus other cut-points among the COPD population, were evaluated post hoc. Findings: Most participants had Eos >2%; 70.7% with spirometry-defined COPD and 65.5% with normal lung function. Older age, male gender, and severe current asthma were significantly associated with Eos >2% in COPD subjects. The Eos 2% COPD group had higher reported rates of previous heart attack and anemia. Among participants with normal lung function, Eos >2% was associated with being male, being overweight/obese, older age, hay fever, and congestive heart failure. Interpretation: In this large US-based cohort, Eos >2% was prevalent in participants with COPD and normal lung function. Among participants with COPD, Eos >2% was associated with specific characteristics including lower rates of some co-morbidities; however, the clinical implications and relationships between Eos levels, COPD mechanisms, and risk of outcomes require further evaluation.
Introduction
As chronic lower respiratory conditions, including chronic obstructive pulmonary disease (COPD), are the third leading cause of death in the United States [1] , significant research has been conducted to better understand the heterogeneity of COPD and maximize patient outcomes. Guidelines, including the Global initiative for chronic Obstructive Lung Disease (GOLD) consensus report, now identify subgroups of patients and specific disease phenotypes when recommending optimal treatment regimens [2, 3] .
To better understand COPD heterogeneity and predict outcomes, biomarkers continue to be an important area of research [4e6] . Although sputum and tissue eosinophils have been established as a measure of inflammation in asthma phenotypes [7] , increasing evidence suggests that blood eosinophil levels (Eos) may be related to disease phenotypes and treatment response in COPD [3,8e11] . This analysis examined the prevalence of Eos levels >2% and identified characteristics associated with Eos >2% among subjects with COPD in a US population-based cohort.
Methods

Study design
Data from the National Health And Nutrition Examination * Funding: Funded by GSK (study number PRJ2320). Survey (NHANES) for 2007e2010, combining data from the 2007e2008 and 2009e2010 surveys, were used in this analysis. As the data collection methodology used in the 2007e2008 and 2009e2010 surveys was the same for the variables included in this analysis, the data could be combined. NHANES is a cross-sectional, clinical patient survey program of the National Center for Health Statistics of the Centers for Disease Control and Prevention, which has been ongoing for more than 50 years. Since 1999, more regularly recurring surveys have been conducted to characterize population health in the United States [12] . The NHANES survey has been used extensively to study the US COPD population [13e16] , and employs a stratified multistage clustered probability sampling strategy to ensure generalizability to the non-institutionalized US population. Questionnaires are completed in participants' households, with laboratory measures and physical examinations, including pulmonary function testing, completed in specially equipped mobile examination centers.
Cohort identification
Participants who were 6e79 years of age with no disqualifying medical conditions were eligible for spirometry and administered lung function testing in accordance with American Thoracic Society standards [17] . For this analysis, pre-bronchodilator values meeting acceptable quality standards were used to identify subjects with COPD, who were categorized based on the 2006 GOLD COPD criteria: a forced expiratory volume in the first second (FEV 1 )/ forced vital capacity (FVC) ratio <0.7 and a FEV 1 80% of predicted (stage I), 50e79% of predicted (stage II), 30e49% of predicted (stage III), or <30% of predicted (stage IV) [18] . Predicted values for spirometry accounted for age, sex, weight, height, and race/ ethnicity [19] . Post-bronchodilator values were obtained on a limited basis but were not used in this analysis. Subjects with questionable or invalid results were excluded [20] . Participants in the analysis were required to be 40 years old and have a GOLD spirometry-defined classification of stage I, II, III, or IV, with stage III and IV considered as severe COPD. Participants were also required to have non-missing Eos counts and Eos percentages as a function of the total white blood cell counts.
As a post-hoc analysis, participants with 'normal' lung function were utilized as a comparison group. 'Normal' lung function was defined as having no evidence of respiratory disease: adults 40e79 years with no evidence of restriction (FEV 1 /FVC ratio 0.7 with FVC <80% of predicted) [13] and no self-reported current asthma, chronic bronchitis, emphysema, and/or bringing up phlegm on most days in the prior 3-month period. Normal lung function subjects were also required to have Eos measurements.
As a post-hoc sensitivity analysis, the factors associated with higher (Eos >4%) and lower (Eos 1%) blood eosinophils, and based on a cut-point of 200 cells per ml, were also examined.
Clinical characteristics
Subject demographics, smoking status, Eos levels, and comorbidities, along with any self-reported diagnoses of chronic bronchitis, emphysema, and bringing up phlegm most days in the prior 3-month period, were characterized and included in the modeling.
Subject demographics and smoking were classified as follows: age (40e49, 50e59, 60e69, and 70e79 years); race/ethnicity (Caucasian, non-Hispanic black, or Mexican-American); body mass index (BMI; missing, <18. cigarettes in their lifetime).
Subject co-morbidities were determined based on self-reported diagnosis of medical conditions and included asthma, diabetes, treated hypertension, congestive heart failure (CHF), coronary heart disease, heart attack, anemia, liver abnormalities, arthritis, high cholesterol, hay fever, and food allergy. Current asthma status was categorized as no current asthma, current non-severe asthma, or current severe asthma. Current non-severe and severe asthma were based on NHANES definitions. To be classed as having current asthma, subjects were required to answer two questions in the affirmative: 'Has a doctor ever told you that you have asthma?' and 'Do you still have asthma?'. Current severe asthma included subjects with current asthma who additionally fulfilled 2 of the following criteria in the past 12 months: an asthma episode or attack, a visit to emergency department or urgent care because of asthma, 6 attacks of wheezing or whistling, 2 visits to the doctor's office or the hospital emergency department for 1 of the attacks of wheezing or whistling, and/or 8 days of work/school missed due to wheezing or whistling.
Analysis
Data analysis was completed using SAS (Statistical Analysis System, version 9.2; SAS Institute, Cary, NC, USA). The NHANES 2007e2010 sampling frame information (primary sampling units and strata) and the mobile examination center/home examination final weights were used in all of the analyses.
Participant characteristics were summarized using frequency and logistic regression procedures that adjusted for the complex NHANES sampling design and survey weights. Differences in clinical characteristics by Eos level (>2% vs 2%) were tabulated using the chi-square test. To adjust for multiple subject characteristics, logistic regression was used with the outcome as the presence (yes/ no) of Eos >2% as the primary outcome. Explanatory variables included COPD lung function (as per GOLD 2006 guidelines) [18] , chronic bronchitis, emphysema, bringing up phlegm most days in the prior 3-month period, demographics, smoking status, current asthma status, and co-morbidities. Due to the number of clinical characteristics relative to the total sample size and prevalence of Eos >2%, a stepwise model selection strategy was employed, such that explanatory variables entered and remained in the model if the p-values achieved the 0.10 level of significance. If one level within a categorical variable was significant (for age or current asthma status), all levels within the categories were retained. The modeling strategy was repeated excluding participants with any current asthma and current severe asthma and for additional post-hoc blood eosinophil thresholds in participants with COPD (Eos >4%, Eos 1%, Eos >200 cells/ml of blood). Goodness-of-fit statistics were used to evaluate the logistic regression models. Weighted summary statistics are presented that are reflective of the distribution of the US population.
Participant characteristics by Eos levels and predictors of Eos >2% in subjects with normal lung function were described as part of the post-hoc analysis. The analytic strategy described for participants with COPD was also employed for participants with normal lung function. Plots of Eos data were also produced to compare the distributions between participants with COPD and normal lung function. 
Results
Study population
A total of 17,515 subjects in the NHANES 2007e2010 cohorts were eligible for spirometry measurements; of these, 8675 were aged 20e79 and had valid spirometry measurements and data on age, gender, and BMI (necessary for calculation of predicted lung function). After applying all entry criteria, 948 participants with spirometry-defined COPD (FEV 1 /FVC <0.7) and 3123 participants with normal lung function were included in the analysis (Fig. 1) .
Overall, 70.7% of participants with COPD and 65.5% of those with normal lung function had Eos >2% (Table 1) , with similar distributions of Eos percentages (Fig. 2) and count. In participants with COPD, the distribution of Eos levels ranged from 0.4 to 21.3%, with a mean of 3.3% and median of 2.6%. The distribution of Eos among COPD patients by smoking status (current/former vs never) was also similar (see Supplementary Fig. 1 ). Eos levels among participants with normal lung function ranged from 0.4 to 24.0%, with a mean of 2.9% and median of 2.4%. Participants with COPD without co-morbid current asthma (non-severe or severe) had a similar proportion of Eos >2% (69.6% [data not shown]).
COPD subjects were mostly classified as having milder disease (58.0% were classed as GOLD stage I, 36.6% as stage II, and 5.4% as stage III or IV). The majority of COPD subjects were male (59.7%), aged 50e69 (61.2%), and current/former smokers (70.7%), with 11.7% reporting any concomitant current asthma. As expected, participants with normal lung function and no current respiratory disease tended to be younger (40.9% were 40e49 years) and never smokers (58.6%).
Participants with COPD and Eos >2% were significantly (chisquare test p < 0.05 comparing >2% vs 2%) more likely to be older; male; have any current asthma, current severe asthma, or severe COPD (GOLD stage III/IV); and were less likely to have been diagnosed with anemia (Table 2) . Among the population with normal lung function and using the same cut-point, being male, overweight or obese, prescribed hypertension treatment, and diagnosed with coronary heart disease, hay fever, or congestive heart failure, were each associated with Eos >2%, while smoking status (former vs never smokers) was marginally significant (Table 2) .
Logistic regression modeling was used to identify factors independently associated with Eos >2%. Among the COPD population, older age, being male, and having current severe asthma versus no current asthma were factors associated with Eos >2%. In contrast, subjects with Eos 2% were more likely to have a history of heart attack or anemia than those with Eos >2% (Fig. 3A) .
When excluding COPD subjects with any current asthma or with current severe asthma, factors associated with Eos >2% were generally similar to the primary COPD analysis (see Supplementary  Fig. 2 ). However, when excluding subjects with any current asthma, subjects with Eos 2% were more likely to have a history of CHF or diabetes, rather than heart attack and anemia. Among participants with normal lung function, Eos >2% was independently associated with being male, being overweight or obese, older age, and prior diagnosis of CHF and hay fever (Fig. 3B) .
A post-hoc analysis evaluated the sensitivity of the results to the chosen Eos cut-point, as well as to Eos cell counts, in patients with COPD. In patients with COPD, the association with current severe asthma was also observed with higher Eos values (Eos >4%; Fig. 4A ).
Eos 1% was associated with CHF and anemia, consistent with participants with Eos <2%. Eos 1% was also associated with nonsevere asthma (vs no asthma) and food allergy (Fig. 4B) . Utilizing a cut-point of 200 cells per ml of blood found similar results to the primary endpoint. Eos >200 cells per ml was associated with severe asthma (vs no asthma) and a lower risk of anemia (see Supplementary Fig. 3 ).
Discussion
In this nationally representative dataset of the US population, Eos >2% was prevalent in subjects with COPD (70.7% of participants, estimated 12.8 million population), which is consistent with observations from clinical trial populations [10] , and associated with increased age, male gender, current asthma severity, and a lower risk of some co-morbidities. Factors associated with Eos >2% were similar in sensitivity analyses excluding subjects with current asthma. In contrast to what might be hypothesized, the distribution of Eos levels was similar between subjects with COPD and those with normal lung function, as well as by smoking status among subjects with COPD. Among participants with normal lung function, Eos >2% was associated with male gender and older age (as in the COPD subgroup); however, being overweight or obese, and having been diagnosed with CHF or hay fever were the other factors more likely to be seen in those with Eos >2%.
There is some suggestion that subjects with lower Eos (<2%) have more severe COPD and/or co-morbidities, but the clinical importance is not fully understood. In a longitudinal analysis of the ECLIPSE cohort (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints; NCT00292552), COPD patients with persistent eosinophilia (2%) had significantly higher FEV 1 % predicted and fat-free mass, and lower St George's Respiratory Questionnaire (SGRQ) and Modified Medical Research Council Dyspnea scores [21] . However, the differences were not considered clinically important. A greater progression of emphysema and .7); (B) subjects with normal lung function with FEV 1 /FVC ratio 0.7, and FVC % predicted 80%, and no self-reported current asthma, chronic bronchitis, emphysema, and/or bringing up phlegm most days in the prior 3-month period. Multivariate regression stepwise model (p entry 0.1 e p retain 0.1 in the model) of factors associated with blood Eos levels >2% vs 2% among NHANES 2007e2010 subjects, aged 40 years, with blood Eos data on both Eos % and Eos count. COPD ¼ chronic obstructive pulmonary disease. CHF ¼ congestive heart failure. Eos ¼ blood eosinophil levels. FEV 1 ¼ forced expiratory volume in the first second. FVC ¼ forced vital capacity. GOLD ¼ Global initiative for chronic Obstructive Lung Disease.
worsening in SGRQ score was observed in patients with persistent lower Eos counts. In the SPIROMICS study, subjects with lower baseline Eos (<1%) had more severe COPD, evidenced by a greater degree of obstruction, shorter 6-minute walk distances, and higher numbers of exacerbations, and were more commonly GOLD stage III or IV [22] . Associations with more severe COPD were not noted in this study, although the results suggest a greater prevalence of comorbidities among subjects with Eos 2% including prior heart attack and anemia (also diabetes and CHF when excluding those with any current asthma). Associations with other 'low eosinophil' cut-points in our analysis (e.g., Eos 1%) included an increased risk of anemia and CHF.
The increase in co-morbidities in the Eos 2% participants with COPD may be due to underlying genetic differences in response to inhalation of noxious agents, particularly cigarette smoke [23] .
Bacterial infections are also known to cause eosinopenia and the Eos 2% group may have greater bacterial colonization [24] . This hypothesis is somewhat supported by the higher incidence of anemia in the Eos 2% group and Eos 1%, as anemia is associated with chronic inflammatory conditions, including infection [25, 26] . Interestingly, the comparison between subjects with COPD and those with normal lung function revealed potentially conflicting results for the association between Eos and CHF. Among COPD subjects without any current asthma, Eos >2% was associated with a lower risk of CHF, while in subjects with normal lung function, Eos >2% was associated with a greater risk of CHF diagnosis. The explanation for this is unclear and requires further research. The association between Eos 1% and non-severe asthma and food allergy, which are characterized by eosinophilic response, are also unclear, but may be spurious and related to the small sample size of patients with both Eos 1% and either of these conditions. Eos measurements as a percentage of white blood cells versus a count in cells/mL are correlated [10] ; therefore, an evaluation of patient characteristics associated with Eos >200 cells/mL found similar associations with severe asthma and anemia to those found using the >2% cut-point in the populations of interest. Analyses utilizing a cut-point based on cell counts were limited, however, due to the structure of the NHANES data. Data on Eos counts in the NHANES dataset are presented as 1000 cells/ml and rounded to one decimal place, with values ranging from 0.1 to 1.6, a median of 0.2, and 25th/75th percentiles of 0.1 and 0.3, respectively, among the COPD subjects in this analysis. These values only allow for categorization of patients by Eos count to the nearest 100 cells/ml, and do not allow for more granular cut-points, such as 150 cells/ml. Due to the distribution of Eos counts and rounding manipulation inherent to the NHANES dataset, analyses based on other cut-points were not feasible.
This analysis does have certain limitations. Lung function measurement in NHANES is limited to those <80 years of age. In addition, participants were ineligible to receive spirometry if they had health conditions that would make them uncomfortable or potentially put their health at risk (e.g., a physical problem with forceful expiration, taking supplemental oxygen, recent surgery of the eye, chest or abdomen, recent heart attack, or current chest pain). These exclusions may have resulted in underrepresentation of subjects with more severe COPD from this sample population. Further, lung function was measured at a single time point using a fixed cut-off, and this analysis utilized pre-bronchodilator values; thus, there may have been some misclassification of COPD according to current guidelines [2] . Post-bronchodilator values were not used due to attrition (n ¼ 316 with post-bronchodilator confirmed COPD) and to ensure adequate sample size. Participants excluded from the post-bronchodilator measurements included those who declined, plus those with specified cardiovascular conditions, select medications, and recent bronchodilator use. Despite these limitations, COPD classification based on spirometry may offer advantages over self-reported diagnosis alone due to challenges in distinguishing between asthma and COPD in a clinical setting without lung function tests, particularly in patients over 40 years [27] . Eos cell count may be a more meaningful measurement to identify patients in a clinical setting, but, as stated above, the structure of the NHANES dataset and distribution of Eos cell counts did not allow for further analysis by other Eos cut-points. Although a more robust analysis of Eos cell count cut-points was not possible, there is a concordance between Eos % and Eos counts [10] . Finally, as the assessments were cross-sectional, it is not possible to determine the direction of the relationship between Eos levels and co-morbidities or longitudinal COPD outcomes.
Conclusion
Mounting evidence suggests that Eos may be a useful biomarker in COPD. In our nationally representative US population, increases in Eos levels are associated with increased age, male gender, and current severe asthma. This may be clinically important as other studies have found that Eos levels may affect response to oral and inhaled corticosteroids [8, 28] . Lower Eos values may also be clinically important, as COPD patients with lower Eos (2%) exhibit an increased risk of co-morbidities (i.e., anemia and CHF) and may not be as responsive to corticosteroids, warranting closer clinical monitoring. While these associations are interesting, the clinical significance and relationship between COPD disease mechanisms and outcomes requires further evaluation.
